NCT07087262 is a Phase 1 clinical trial of SNH-119014 in Hemoglobinopathy, sponsored by ScinnoHub Pharmaceutical Co., Ltd..

Who is sponsoring NCT07087262?

NCT07087262 is sponsored by ScinnoHub Pharmaceutical Co., Ltd..

What drugs are being tested in NCT07087262?

Interventions in NCT07087262: SNH-119014, Placebo.

What condition does NCT07087262 study?

NCT07087262 studies Hemoglobinopathy.

Is NCT07087262 still recruiting?

NCT07087262 is currently recruiting now. Last updated 25 July 2025.

Last reviewed 2025-07-25 · How we verify

NCT07087262

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of SNH-119014 in Healthy Volunteers

Recruiting now Phase 1 Last updated 25 July 2025

What this trial tests

Phase 1 trial testing SNH-119014 in Hemoglobinopathy in 96 participants. Currently enrolling.

Timeline

27 June 2025

Primary endpoint
28 March 2026

28 March 2026

Quick facts

Lead sponsor	ScinnoHub Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	96
Start date	27 June 2025
Primary completion	28 March 2026
Estimated completion	28 March 2026
Sites	1 location across China

Drugs / interventions tested

SNH-119014 — full drug profile →
Placebo

Conditions studied

Hemoglobinopathy — all drugs for Hemoglobinopathy →

Sponsor

ScinnoHub Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with Hemoglobinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemoglobinopathy

Currently open trials in the same condition.

NCT07373639 — A Long-term Follow-up Study in Patients Who Received BEAM-101 · recruiting
NCT06313398 — Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling · EARLY_PHASE1 · recruiting

Other ScinnoHub Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07127042 — Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA） · Phase 2 · recruiting
NCT07169214 — Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding · Phase 1 · recruiting
NCT07169240 — Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07087262 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ScinnoHub Pharmaceutical Co., Ltd.
Last refreshed: 25 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07087262.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing